Oui, des habitudes de vie comme l'alimentation et l'exercice peuvent influencer le risque hormonal.
Habitudes de vieRisque hormonal
#5
Les traitements antérieurs influencent-ils le risque ?
Certains traitements hormonaux antérieurs peuvent affecter le risque de développer des troubles.
Traitements hormonauxRisque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Cholestenone 5 alpha-reductase : Questions médicales les plus fréquentes",
"headline": "Cholestenone 5 alpha-reductase : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Cholestenone 5 alpha-reductase : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-22",
"dateModified": "2026-07-12",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Cholestenone 5 alpha-reductase"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Oxidoreductases acting on CH-CH group donors",
"url": "https://questionsmedicales.fr/mesh/D044925",
"about": {
"@type": "MedicalCondition",
"name": "Oxidoreductases acting on CH-CH group donors",
"code": {
"@type": "MedicalCode",
"code": "D044925",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.660"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Cholestenone 5 alpha-reductase",
"alternateName": "Cholestenone 5 alpha-Reductase",
"code": {
"@type": "MedicalCode",
"code": "D042944",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Francesco Del Giudice",
"url": "https://questionsmedicales.fr/author/Francesco%20Del%20Giudice",
"affiliation": {
"@type": "Organization",
"name": "Department of Urology, Sapienza University of Rome, Rome, Italy."
}
},
{
"@type": "Person",
"name": "Thiraphat Saengmearnuparp",
"url": "https://questionsmedicales.fr/author/Thiraphat%20Saengmearnuparp",
"affiliation": {
"@type": "Organization",
"name": "Department of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand."
}
},
{
"@type": "Person",
"name": "Nipon Chattipakorn",
"url": "https://questionsmedicales.fr/author/Nipon%20Chattipakorn",
"affiliation": {
"@type": "Organization",
"name": "Neurophysiology Unit, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand; Cardiac Electrophysiology Unit, Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai 50200, Thailand."
}
},
{
"@type": "Person",
"name": "James L Mohler",
"url": "https://questionsmedicales.fr/author/James%20L%20Mohler",
"affiliation": {
"@type": "Organization",
"name": "Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA."
}
},
{
"@type": "Person",
"name": "Bannakij Lojanapiwat",
"url": "https://questionsmedicales.fr/author/Bannakij%20Lojanapiwat",
"affiliation": {
"@type": "Organization",
"name": "Department of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Effect of 5-alpha reductase inhibitors in animal models of Parkinson's disease.",
"datePublished": "2024-09-29",
"url": "https://questionsmedicales.fr/article/39353534",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.yfrne.2024.101156"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effect of 5-Alpha Reductase Inhibitors on Magnetic Resonance Imaging and Prostate Cancer Detection.",
"datePublished": "2024-02-05",
"url": "https://questionsmedicales.fr/article/38397430",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/biom14020193"
}
},
{
"@type": "ScholarlyArticle",
"name": "Diagnosis of prostate cancer with magnetic resonance imaging in men treated with 5-alpha-reductase inhibitors.",
"datePublished": "2023-10-03",
"url": "https://questionsmedicales.fr/article/37787941",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00345-023-04634-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Suicide and Intentional Self-Harm among Older Men Treated with 5-Alpha Reductase Inhibitor or Alpha-Blockers for Benign Prostatic Hyperplasia.",
"datePublished": "2024-06-14",
"url": "https://questionsmedicales.fr/article/38880345",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.urology.2024.06.013"
}
},
{
"@type": "ScholarlyArticle",
"name": "Dutasteride, a 5 alpha reductase inhibitor, could be associated with the exacerbation of inflammation in patients with benign prostatic hyperplasia.",
"datePublished": "2024-10-23",
"url": "https://questionsmedicales.fr/article/39441013",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/iju.15612"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Oxidoreductases",
"item": "https://questionsmedicales.fr/mesh/D010088"
},
{
"@type": "ListItem",
"position": 5,
"name": "Oxidoreductases acting on CH-CH group donors",
"item": "https://questionsmedicales.fr/mesh/D044925"
},
{
"@type": "ListItem",
"position": 6,
"name": "Cholestenone 5 alpha-reductase",
"item": "https://questionsmedicales.fr/mesh/D042944"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Cholestenone 5 alpha-reductase - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Cholestenone 5 alpha-reductase",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-09-12",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Cholestenone 5 alpha-reductase",
"description": "Comment diagnostiquer une déficience en 5 alpha-réductase ?\nQuels tests sont utilisés pour évaluer l'activité de l'enzyme ?\nQuels symptômes peuvent indiquer un problème avec cette enzyme ?\nLa biopsie est-elle nécessaire pour le diagnostic ?\nPeut-on diagnostiquer cette condition chez les nouveau-nés ?",
"url": "https://questionsmedicales.fr/mesh/D042944#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Cholestenone 5 alpha-reductase",
"description": "Quels sont les symptômes d'une déficience en 5 alpha-réductase ?\nLes femmes peuvent-elles présenter des symptômes liés à cette enzyme ?\nComment se manifeste l'hirsutisme lié à cette condition ?\nY a-t-il des symptômes psychologiques associés ?\nLes symptômes varient-ils selon l'âge ?",
"url": "https://questionsmedicales.fr/mesh/D042944#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Cholestenone 5 alpha-reductase",
"description": "Peut-on prévenir les troubles liés à cette enzyme ?\nLes tests génétiques peuvent-ils aider à la prévention ?\nY a-t-il des conseils pour les familles à risque ?\nL'éducation sur la santé reproductive est-elle importante ?\nLes dépistages réguliers sont-ils recommandés ?",
"url": "https://questionsmedicales.fr/mesh/D042944#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Cholestenone 5 alpha-reductase",
"description": "Quels traitements sont disponibles pour cette condition ?\nLes médicaments peuvent-ils aider à réguler les symptômes ?\nLa thérapie hormonale est-elle efficace ?\nY a-t-il des traitements non médicaux recommandés ?\nLa chirurgie est-elle une option pour tous les patients ?",
"url": "https://questionsmedicales.fr/mesh/D042944#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Cholestenone 5 alpha-reductase",
"description": "Quelles complications peuvent survenir avec cette condition ?\nLes complications sont-elles réversibles ?\nY a-t-il un risque accru de maladies associées ?\nLes complications affectent-elles la qualité de vie ?\nComment gérer les complications psychologiques ?",
"url": "https://questionsmedicales.fr/mesh/D042944#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Cholestenone 5 alpha-reductase",
"description": "Quels sont les facteurs de risque pour cette condition ?\nL'âge joue-t-il un rôle dans le risque ?\nLes facteurs environnementaux influencent-ils cette condition ?\nLes habitudes de vie affectent-elles le risque ?\nLes traitements antérieurs influencent-ils le risque ?",
"url": "https://questionsmedicales.fr/mesh/D042944#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en 5 alpha-réductase ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic se fait par des tests hormonaux et génétiques pour évaluer les niveaux d'androgènes."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité de l'enzyme ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins mesurant les niveaux de dihydrotestostérone (DHT) sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec cette enzyme ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies de développement sexuel ou des troubles hormonaux peuvent indiquer un problème."
}
},
{
"@type": "Question",
"name": "La biopsie est-elle nécessaire pour le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "La biopsie n'est généralement pas nécessaire, les tests sanguins suffisent souvent."
}
},
{
"@type": "Question",
"name": "Peut-on diagnostiquer cette condition chez les nouveau-nés ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des tests peuvent être effectués à la naissance si des anomalies sont suspectées."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une déficience en 5 alpha-réductase ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des anomalies génitales, une virilisation incomplète et des troubles menstruels."
}
},
{
"@type": "Question",
"name": "Les femmes peuvent-elles présenter des symptômes liés à cette enzyme ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des déséquilibres hormonaux peuvent entraîner des symptômes comme l'hirsutisme."
}
},
{
"@type": "Question",
"name": "Comment se manifeste l'hirsutisme lié à cette condition ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'hirsutisme se manifeste par une pilosité excessive sur le visage et le corps chez les femmes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes psychologiques associés ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles de l'image corporelle et de l'anxiété peuvent survenir en raison des symptômes physiques."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'âge ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent se manifester différemment selon l'âge et le stade de développement."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les troubles liés à cette enzyme ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention, mais un diagnostic précoce peut aider à gérer les symptômes."
}
},
{
"@type": "Question",
"name": "Les tests génétiques peuvent-ils aider à la prévention ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques peuvent identifier les porteurs et aider à la prise de décision reproductive."
}
},
{
"@type": "Question",
"name": "Y a-t-il des conseils pour les familles à risque ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les familles à risque devraient consulter un conseiller génétique pour discuter des options."
}
},
{
"@type": "Question",
"name": "L'éducation sur la santé reproductive est-elle importante ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'éducation peut aider à sensibiliser et à identifier les symptômes précoces."
}
},
{
"@type": "Question",
"name": "Les dépistages réguliers sont-ils recommandés ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dépistages réguliers peuvent être bénéfiques pour les personnes à risque ou présentant des symptômes."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour cette condition ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des thérapies hormonales et, dans certains cas, une chirurgie corrective."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils aider à réguler les symptômes ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des médicaments comme les anti-androgènes peuvent aider à gérer les symptômes."
}
},
{
"@type": "Question",
"name": "La thérapie hormonale est-elle efficace ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la thérapie hormonale peut aider à rétablir l'équilibre hormonal et réduire les symptômes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements non médicaux recommandés ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des approches psychologiques et de soutien peuvent être bénéfiques pour les patients."
}
},
{
"@type": "Question",
"name": "La chirurgie est-elle une option pour tous les patients ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la chirurgie est généralement réservée aux cas graves ou aux anomalies physiques significatives."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec cette condition ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des troubles psychologiques, des problèmes de fertilité et des anomalies physiques."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées ou améliorées avec un traitement approprié."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de maladies associées ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients peuvent avoir un risque accru de maladies métaboliques et hormonales."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent significativement affecter la qualité de vie et le bien-être psychologique."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications psychologiques ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un soutien psychologique et des thérapies peuvent aider à gérer les complications psychologiques."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour cette condition ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des anomalies génétiques et des déséquilibres hormonaux."
}
},
{
"@type": "Question",
"name": "L'âge joue-t-il un rôle dans le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains symptômes peuvent apparaître à des âges spécifiques, influençant le risque."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux influencent-ils cette condition ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs environnementaux peuvent interagir avec des prédispositions génétiques, augmentant le risque."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie affectent-elles le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes de vie comme l'alimentation et l'exercice peuvent influencer le risque hormonal."
}
},
{
"@type": "Question",
"name": "Les traitements antérieurs influencent-ils le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains traitements hormonaux antérieurs peuvent affecter le risque de développer des troubles."
}
}
]
}
]
}
Neurophysiology Unit, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand; Cardiac Electrophysiology Unit, Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai 50200, Thailand.
Publications dans "Cholestenone 5 alpha-reductase" :
Department of Pharmacological and Biomolecular Sciences, Center of Excellence on Neurodegenerative Diseases, Università degli Studi di Milano, Milan, Italy.
Publications dans "Cholestenone 5 alpha-reductase" :
Department of Pharmacological and Biomolecular Sciences, Center of Excellence on Neurodegenerative Diseases, Università degli Studi di Milano, Milan, Italy.
Publications dans "Cholestenone 5 alpha-reductase" :
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Department of Urology, Minimally Invasive Surgery center, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. gzgy_dengtuo@sina.com.
Publications dans "Cholestenone 5 alpha-reductase" :
Department of Urology, Minimally Invasive Surgery center, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. 94302304@qq.com.
Publications dans "Cholestenone 5 alpha-reductase" :
Department of Urology, Minimally Invasive Surgery center, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. 2516651329@qq.com.
Publications dans "Cholestenone 5 alpha-reductase" :
Department of Urology, Minimally Invasive Surgery center, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. 515585921@qq.com.
Publications dans "Cholestenone 5 alpha-reductase" :
Department of Urology, Minimally Invasive Surgery center, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. gzgyzgh@vip.tom.com.
Publications dans "Cholestenone 5 alpha-reductase" :
Parkinson's disease (PD) is characterized by motor symptoms due to loss of brain dopamine and non-motor symptoms, including gastrointestinal disorders. Although there is no cure for PD, symptomatic tr...
Concerns exist regarding the effects of 5-alpha reductase inhibitors (5-ARIs) on multipa-rametric magnetic resonance imaging (mpMRI) and clinically significant prostate cancer (csPCa) detection. Our o...
The primary aim of this study was to evaluate if exposure to 5-alpha-reductase inhibitors (5-ARIs) modifies the effect of MRI for the diagnosis of clinically significant Prostate Cancer (csPCa) (ISUP ...
This study is a multicenter cohort study including patients undergoing prostate biopsy and MRI at 24 institutions between 2013 and 2022. Multivariable analysis predicting csPCa with an interaction ter...
705 patients (9%) were treated with 5-ARIs [median age 69 years, Interquartile range (IQR): 65, 73; median PSA 6.3 ng/ml, IQR 4.0, 9.0; median prostate volume 53 ml, IQR 40, 72] and 6913 were 5-ARIs n...
Exposure to 5-ARIs does not affect the association of PIRADS score with csPCa. Higher rates of high-grade PCa were detected in treated patients, but most were clearly visible on MRI as PIRADS 4 and 5 ...
The present study was registered at ClinicalTrials.gov number: NCT05078359....
To compare the risk of intentional self-harm (ISH) and suicide in older men using 5-α reductase inhibitors (5-ARIs) and alpha-blockers for benign prostatic hyperplasia (BPH). Observational research of...
Using Medicare data linked to the National Death Index (NDI) from 2007-2016, we implemented a retrospective cohort design in males aged ≥65 years who initiated 5-ARI or alpha-blocker use for BPH. ISH ...
The event rates for ISH and suicide, respectively, were 0.314 and 0.308 per 1000 person-years (PY) among 5-ARI users (n=181,675), and 0.364 and 0.382 per 1000PY among alpha-blocker users (n=850,476). ...
5-ARI use was not associated with an increased risk for ISH or suicide compared to alpha-blocker use in older men with BPH. Study limitations included low event rates and potentially low sensitivity f...
α-1 blockers and dutasteride are widely used as agents to treat benign prostatic hyperplasia (BPH); the impact of these drugs on prostatic inflammation is still unclear. Herein, we investigated the im...
Tissue specimens were obtained from 143 BPH patients who were administered α-1 blockers up until their operation. Thirty-three of the patients had also been treated with dutasteride before the procedu...
Comparison of the monotherapy and combination therapy groups showed no significant differences in the parameters of the urodynamic study or degree of chronic prostatic inflammation, whereas the IPSS t...
The present study showed that despite their ameliorating effect on prostatic hyperplasia, dutasteride contributed significantly to chronic prostatic inflammation....
Several studies have reported side effects of finasteride (FIN), such as anxiety/depression in young men. Obesity is also positively associated with anxiety/depression symptoms; however, the impacts o...
This study combined the bioinformatics and...
Gene expression and clinical data were obtained from public databases. The prognosis was evaluated using survival, multifactor Cox, enrichment, and mutation analyses. This was then verified through...
The expression level of...
Finasteride, a steroid 5-alpha reductase inhibitor, is commonly used for the treatment of benign prostatic hyperplasia and hair loss. However, despite continued use, its environmental implications hav...
To compare the urological and sexual outcomes of using either tamsulosin/finateride or tadalafil/finasteride as combination therapies in patients with large prostate....
Selection criteria included prostate volume > 40 ml and IPSS > 7. Patients with severe erectile dysfunction (IIEF-erectile functions ≤ 10) were excluded. Patients were randomized into group I (tamsulo...
At 4th and 12th weeks, 131 and 127 patients were available in both groups, respectively. Both groups showed significant LUTS improvement (IPSS changes: - 4.9 ± 2.7 and - 4.3 ± 2.9 at 4th week and - 6....
Within three months, both combinations are comparably effective in improving BPH related LUTS. Tamsulosin/finasteride provided significantly better Qmax only at 4th week. Tadalafil/finasteride had the...
The medical therapy of prostatic symptoms (MTOPS) trial randomized men with symptoms of benign prostatic hyperplasia (BPH) and followed response of treatment with a 5α-reductase inhibitor (5ARI), an a...
Surgical BPH (S-BPH) tissue was defined as benign prostatic tissue collected from the transition zone (TZ) of patients who failed medical therapy while control tissue termed Incidental BPH (I-BPH) was...
Transcriptomic analysis between S-BPH (n = 30) and I-BPH (n = 14) using a twofold cutoff (p < 0.05) identified 377 DEG (termed BPH377) and a cutoff < 0.05 identified 3377 DEG (termed BPH3377). Within ...
Reduction analysis of BPH and 3D organoid culture uncovered networks previously identified in prostatic development as being reinitiated in BPH. Identification of these pathways provides insight into ...